Adamas Pharmaceuticals
Earnings Date & Report
Last updated:
Adamas Pharmaceuticals’s last earnings date was on 10 Nov 2021. It reported its quarterly earnings per share (EPS) reaching -$0.43, falling behind the estimated value of -$0.22 by $0.21. The company’s quarterly earnings increased by 28.35% to 25.9M US dollars compared to the same quarter of the previous year. Over the last year, Adamas Pharmaceuticals’s earnings per share have dropped by 2.38%.
Adamas Pharmaceuticals stock Earnings report, Estimates & History
| 2017-02-28 | -0.8 | -0.68 |
|---|---|---|
| 2017-05-09 | -0.71 | -0.72 |
| 2017-08-08 | -0.81 | -0.93 |
| 2017-11-02 | -0.98 | -1.04 |
| 2018-02-22 | -1.18 | -1.27 |
| 2018-05-03 | -1.37 | -1.35 |
| 2018-08-02 | -1.41 | -1.26 |
| 2018-11-01 | -1.34 | -1.22 |
| 2019-03-04 | -1.34 | -1.06 |
| 2019-05-09 | -1.15 | -1.08 |
| 2019-08-08 | -0.98 | -0.9 |
| 2019-11-07 | -0.89 | -0.99 |
| 2020-02-25 | -0.85 | -0.83 |
| 2020-05-07 | -0.77 | -0.59 |
| 2020-08-06 | -0.61 | -0.37 |
| 2020-11-05 | -0.48 | -0.42 |
| 2021-02-23 | -0.51 | -0.64 |
| 2021-05-10 | -0.51 | -0.36 |
| 2021-08-09 | -0.27 | -0.27 |
| 2021-11-10 | -0.22 | -0.43 |
Estimated - a value of Apple’s earnings per share estimated by analysts based on its past and current financial statements.
Reported - a real value of Apple’s earnings per share reported by the company.
Adamas Pharmaceuticals stock earnings history by quarter
| Date | Estimated EPS | Reported EPS | Estimated revenue | Actual revenue | Earnings call | |
|---|---|---|---|---|---|---|
| 10 Nov 2021 | Missed | -$0.22 | -$0.43 | 22.12M | 25.89M | |
| 9 Aug 2021 | Matched | -$0.27 | -$0.27 | 21.97M | 21.97M | Earnings Call Transcript |
| 10 May 2021 | Beat | -$0.51 | -$0.36 | 24.99M | 19.31M | Earnings Call Transcript |
| 23 Feb 2021 | Missed | -$0.51 | -$0.64 | 15.65M | 21.01M | Earnings Call Transcript |
| 5 Nov 2020 | Beat | -$0.48 | -$0.42 | 1.37M | 20.17M | |
| 6 Aug 2020 | Beat | -$0.61 | -$0.37 | 30.98M | 18.79M | Earnings Call Transcript |
| 7 May 2020 | Beat | -$0.77 | -$0.59 | 18.89M | 14.48M | |
| 25 Feb 2020 | Beat | -$0.85 | -$0.83 | 16.74M | 16.34M | Earnings Call Transcript |
| 7 Nov 2019 | Missed | -$0.89 | -$0.99 | 12.52M | 13.93M | Earnings Call Transcript |
| 8 Aug 2019 | Beat | -$0.98 | -$0.9 | 13.81M | 12.69M | Earnings Call Transcript |
| 9 May 2019 | Beat | -$1.15 | -$1.08 | 12.42M | 11.66M | Earnings Call Transcript |
| 4 Mar 2019 | Beat | -$1.34 | -$1.06 | 16.83M | 13.31M | Earnings Call Transcript |
| 1 Nov 2018 | Beat | -$1.34 | -$1.22 | 11.65M | 10.61M | Earnings Call Transcript |
| 2 Aug 2018 | Beat | -$1.41 | -$1.26 | 8.46M | 7.56M | |
| 3 May 2018 | Beat | -$1.37 | -$1.35 | 2.59M | 2.55M | Earnings Call Transcript |
| 22 Feb 2018 | Missed | -$1.18 | -$1.27 | 527.74K | 568K | Earnings Call Transcript |
| 2 Nov 2017 | Missed | -$0.98 | -$1.04 | 942 | 1K | Earnings Call Transcript |
| 8 Aug 2017 | Missed | -$0.81 | -$0.93 | 1.74K | 2K | |
| 9 May 2017 | Missed | -$0.71 | -$0.72 | N/A | N/A | Earnings Call Transcript |
| 28 Feb 2017 | Beat | -$0.8 | -$0.68 | 43.52K | 37K | |
Adamas Pharmaceuticals Earnings report FAQs
When is Adamas Pharmaceuticals's next Earnings date?
The company has not set the next earnings date yet. The latest Adamas Pharmaceuticals's earnings date was on 5 Nov 2020.
What are earnings?
Earnings are the net income of a company after all taxes and expenses have been deducted. They are the main figure for determining the price of a company's shares.
What does EPS stand for?
EPS stands for earnings per share, which is the basic measure of a company's earnings. It indicates how much money each share earned for the company.
How to calculate earnings per share?
Earnings per share (EPS) can be calculated by dividing a company's net income by the number of common shares outstanding. If the company pays preferred dividends, they are first subtracted from the company’s net income.
Formula:
What is earnings per share estimate?
Earnings estimate is analysts’ prediction of a company’s earnings value in the next quarter or fiscal year based on past and current financial statements of a company. It is an important indicator for both current and future investors.